Insomnia Treatment
Cognitive behavioral therapy for insomnia (CBT-I) is the mandatory first-line treatment for all adults with chronic insomnia, regardless of age or comorbidities, and pharmacologic therapy should only be added if CBT-I alone is unsuccessful. 1
Treatment Algorithm
Step 1: Initial Treatment - CBT-I for All Patients
- CBT-I is a strong recommendation with moderate-quality evidence and should be offered to every adult patient with chronic insomnia before considering medications 1
- This applies equally to:
- Delivery methods include in-person (individual or group), telephone-based, web-based modules, or self-help books 1
- Digital CBT-I is equally effective as in-person therapy 3
Step 2: Pharmacologic Therapy (Only After CBT-I Failure)
Use shared decision-making to discuss benefits, harms, and costs before adding medications 1. The choice depends on patient age and specific characteristics:
For Adults Under 65 Years:
First-line pharmacologic options:
- Dual orexin receptor antagonists (DORAs): Daridorexant, lemborexant, suvorexant
Alternative options:
- Z-hypnotics (zolpidem, eszopiclone, zaleplon): Safe in depression/anxiety but use as-needed or <6 weeks 5
- Low-dose doxepin: Effective for sleep initiation and maintenance, no abuse potential 5
- Trazodone (off-label): Most prescribed off-label treatment due to efficacy and lack of abuse potential 5
For Adults ≥65 Years:
Preferred pharmacologic options (safer in elderly):
- Low-dose doxepin 2
- Prolonged-release melatonin (up to 3 months) 3, 6
- Ramelteon (melatonin receptor agonist) 2
- Dual orexin receptor antagonists (up to 3 months or longer) 3
AVOID in older adults:
- Z-hypnotics (zolpidem, zopiclone, zaleplon) - increased risk with respiratory or cognitive impairment 5
- Benzodiazepines - higher risk profile in elderly 6
Duration of Pharmacologic Treatment
- Benzodiazepines and Z-hypnotics: ≤4 weeks short-term 3; as-needed or <6 weeks nightly use 5
- Orexin receptor antagonists: Up to 3 months or longer in select cases 3
- Prolonged-release melatonin: Up to 3 months in patients ≥55 years 3
- General principle: Use lowest effective dose for shortest duration 5
Medications NOT Recommended
The following should NOT be used for insomnia treatment 3:
- Antihistaminergic drugs (despite being nonprescription)
- Antipsychotics
- Fast-release melatonin
- Ramelteon (conflicting evidence - recommended by some 2 but not by European guidelines 3)
- Phytotherapeutics
Critical Pitfalls to Avoid
Never skip CBT-I: Going directly to medications violates evidence-based guidelines and deprives patients of the most effective long-term treatment 1
Age matters for medication selection: What's safe in younger adults (Z-hypnotics) becomes dangerous in older adults due to falls, cognitive impairment, and respiratory depression 5, 2
Avoid chronic benzodiazepine use: Despite being FDA-approved, these should be limited to ≤4 weeks due to dependence, tolerance, and adverse effects 3
Don't use antihistamines routinely: Though available over-the-counter, they are not recommended by guidelines 3
Screen for underlying causes: Before treating, assess for sleep apnea, restless legs syndrome, narcolepsy, contributing medications, and psychiatric/medical comorbidities 5
Special Considerations by Insomnia Type
- Sleep initiation difficulty: DORAs, Z-hypnotics, trazodone 5
- Sleep maintenance difficulty: DORAs, low-dose doxepin, trazodone 5
- Early morning awakening: DORAs with appropriate half-life 5
The evidence strongly converges on CBT-I as non-negotiable first-line therapy, with the 2016 ACP guideline 1 providing the strongest recommendation (Grade A). Newer evidence from 2023-2025 5, 2, 3 reinforces this while updating pharmacologic options, particularly highlighting DORAs as preferred agents when medications are needed due to their superior safety profile.